Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 40 people enrolled
- Started
- 9 Oct 2023
- Ended
- 8 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Baseline surveys, Cognitive testing and EMAs
- Actiwatch
- suvorexant (or placebo)
- Placebo
- Record updated
- 30 October 2025
Who can take part
- Age
- 60 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Meets Diagnostic and Statistical Manual - Fifth Edition (DSM-5) diagnostic criteria for insomnia disorder
- Insomnia Severity Index total score >10
- Insomnia symptoms must include problems with wake after sleep onset
- Insomnia symptom duration > 6 months
- Baseline self-reported total sleep time < 6.5 hours per night
Who cannot take part
- History of previous allergic reaction, sensitivity, or severe side effects to sedative hypnotics
- CYP3A inhibitors
- High risk for untreated organic sleep disorders other than insomnia (narcolepsy, periodic limb movement disorder, etc) as determined by structured clinical interview and investigator clinical judgment
- Current diagnosis of a major untreated psychiatric disorder(s)
- History of serious suicide attempt within past 5 years
- History of alcohol or substance abuse (including prescription medication abuse) within past 5 years
- Heavy alcohol consumption (e.g., >5 drinks per day or > 14 drinks per week
- Heavy caffeine use [(>2 cups of coffee/day (equivalent)
- Current tobacco or nicotine use
- Refusal to discontinue or intention to initiate OTC or other sleep aids during study period
Where in United States
- University of Maryland, BaltimoreBaltimore, United States
About the trial
What the trial wants to find out
The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with insomnia. The primary hypothesis is that relative to placebo, suvorexant will improve sleep and daytime symptoms. The word "placebo" refers to a harmless pill with no therapeutic effect.
The 2 groups in the trial
- TreatmentTreatment being tested
Participants will start on 10mg suvorexant, po, qhs, including instructions on dosage, expectations, and potential side effects, for two nights. Following this low-dose run-in period, individuals in the treatment condition will be increased to 20mg for a 14-day active treatment period (i.e.,16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing (completed at baseline and post-treatment), as well as EMA surveys, daily sleep diaries, and actigraphy.
Treatment: Baseline surveys, Cognitive testing and EMAs, Actiwatch, and suvorexant (or placebo)
- PlaceboPlacebo, for comparison
Participants in the control condition will take placebo (no drug) pill form, po, qhs, including instructions on dosage, expectations, and potential side effects for (16 nights taking a pill). Other assessments include self-report research questionnaires and cognitive testing, daily sleep diaries, and actigraphy.
Treatment: Baseline surveys, Cognitive testing and EMAs, Actiwatch, and Placebo
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Suvorexant on Cognitive Function and Daytime Symptoms Among Community-dwelling Older Adults With Insomnia: A Placebo-controlled, Randomized Clinical Trial Using Remote Monitoring and Ecological Momentary Assessment
- Publications
- Record updated
- 30 October 2025